Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion (Q39496607)

12 September 2017

Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion (English)

1 reference

12 September 2017

0 references

1 reference

Mitsushige Sugimoto

1

1 reference

12 September 2017

Takahiro Uotani

2

1 reference

12 September 2017

Shu Sahara

3

1 reference

12 September 2017

Hitomi Ichikawa

4

1 reference

12 September 2017

Mihoko Yamade

5

1 reference

12 September 2017

Ken Sugimoto

6

1 reference

12 September 2017

Takahisa Furuta

7

1 reference

12 September 2017

1 April 2014

1 reference

12 September 2017

1 reference

12 September 2017

19

1 reference

12 September 2017

4

1 reference

12 September 2017

312-318

1 reference

Helicobacter pylori infection and the development of gastric cancer

12 September 2017

1 reference

Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial

21 January 2018

1 reference

Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review

21 January 2018

1 reference

A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients

21 January 2018

1 reference

Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin

21 January 2018

1 reference

Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance

21 January 2018

1 reference

Furazolidone-based triple therapy for H pylori gastritis in children

21 January 2018

1 reference

Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities

21 January 2018

1 reference

Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance

21 January 2018

1 reference

New concepts of resistance in the treatment of Helicobacter pylori infections

21 January 2018

1 reference

Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin

21 January 2018

1 reference

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

21 January 2018

1 reference

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

21 January 2018

1 reference

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole

21 January 2018

1 reference

Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype

21 January 2018

1 reference

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

21 January 2018

1 reference

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

21 January 2018

1 reference

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

21 January 2018

1 reference

Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups

21 January 2018

1 reference

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

21 January 2018

1 reference

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

The life and death of Helicobacter pylori

21 January 2018

1 reference

The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin

21 January 2018

1 reference

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

21 January 2018

1 reference

In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis

21 January 2018

1 reference

Pharmacogenomics of proton pump inhibitors

21 January 2018

1 reference

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/HEL.12128

1 reference

release_lowhqolw5ngnrcu2atxvucl3qi

12 September 2017

0 references

1 reference